Morelloflavone

Morelloflavone

SCHEMBL2383075

O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)[C@H]1c1c(O)cc(O)c2c(=O)cc(-c3ccc(O)c(O)c3)oc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 4/20 1.00
PRSS2 P07478 4/20 1.00
PRSS3 P35030 4/20 1.00
CBS P35520 2/20 0.73
KLK1 P06870 1/20 0.57
KLK3 P07288 1/20 0.57
KLK2 P20151 1/20 0.57
KLK7 P49862 1/20 0.57
KLK6 Q92876 1/20 0.57
KLK5 Q9Y337 1/20 0.57
PARP1 P09874 3/20 0.53
PARP2 Q9UGN5 2/20 0.53
BACE1 P56817 2/20 0.53
CDK5 Q00535 2/20 0.50
CDK5R1 Q15078 2/20 0.50
PTPN1 P18031 1/20 0.50
KDM4E B2RXH2 3/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 3/20 0.49
GAA P10253 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morelloflavone SCHEMBL615093 1.00 PRSS1 (1.00) PRSS1PRSS2PRSS3CBSKLK1
SCHEMBL27165462 0.94 PRSS1 (0.90) PRSS1PRSS2PRSS3CBSKLK1
Volkensiflavone SCHEMBL13829450 0.94 PRSS1 (0.89) PRSS1PRSS2PRSS3CBSKLK1
Volkensiflavone SCHEMBL27160551 0.94 PRSS1 (0.89) PRSS1PRSS2PRSS3CBSKLK1
Volkensiflavone SCHEMBL7620161 0.94 PRSS1 (0.89) PRSS1PRSS2PRSS3CBSKLK1
Pancibiflavonol SCHEMBL13829454 0.86 PRSS1 (0.76) PRSS1PRSS2PRSS3CBSKLK1
SCHEMBL30209479 0.77 PRSS1 (0.62) PRSS1PRSS2PRSS3CBSKDM4E
SCHEMBL16263265 0.74 KLK1 (0.72) PRSS1PRSS2PRSS3CBSKLK1
SCHEMBL6360284 0.74 KLK1 (0.72) PRSS1PRSS2PRSS3CBSKLK1
SCHEMBL29414343 0.74 KLK1 (0.72) PRSS1PRSS2PRSS3CBSKLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION ERESINA LLC (US) 2026-04-16 US disclosed
EP-4593859-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION Eresina, LLC (US) 2025-08-06 EP disclosed
WO-2024073011-A1 TOPICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION ERESINA, LLC (US) 2024-04-04 WO disclosed
WO-2024073013-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION ERESINA, LLC (US) 2024-04-04 WO disclosed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO disclosed
CN-106138563-A A kind of pharmaceutical composition treating bladder cancer 济南星懿医药技术有限公司 2016-11-23 CN disclosed
CN-105596415-A Pharmaceutical composition for treating angina pectoris in coronary heart disease and preparation method thereof JINAN XINGYI MED TECH CO LTD 2016-05-25 CN disclosed
CN-105497114-A Pharmaceutical composition for treating dyspepsia and preparation method thereof JINAN XINGYI MED TECH CO LTD 2016-04-20 CN disclosed
CN-105288202-A Pharmaceutical composition for curing infantile cough JINAN XINGYI MED TECH CO LTD 2016-02-03 CN disclosed
CN-105287739-A Medicine composition for treating leucoderma and preparation method thereof JINAN XINGYI MED TECH CO LTD 2016-02-03 CN disclosed
CN-105267289-A Pharmaceutical composition for treating functional dyspepsia and preparation method of pharmaceutical composition JINAN XINGYI MED TECH CO LTD 2016-01-27 CN disclosed
CN-105250357-A Medicine composition for treating child qi deficiency type constipation JINAN XINGYI MED TECH CO LTD 2016-01-20 CN disclosed
US-20110217293-A1 Uses of morelloflavone BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE 2011-09-08 US disclosed
WO-2010014199-A2 USES OF MORELLOFLAVONE THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION COL2A1, COLGALT1, PLOD3 PRSS1 2398/4885PRSS2 1747/4885PRSS3 2316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.